French pharmaceutical giant Sanofi on Friday said the European Medicines Agency had conditionally approved its anti-cancer drug Libtayo, the first drug of its kind to be authorised for use in the EU. The tumour-reducing drug is aimed at patients with the second most common form of skin cancer—cutaneous squamous cell carcinoma (CSCC)—whose cancer is advanced, […]